Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...

Looking further ahead, NHS England envisages savings as a whole from biosimilars of some £400 - £500 million per year by 2021, if it can increase uptake of ‘best value biologic medicines’.

Biosimilars — nearly identical and more affordable alternatives to biologics — can significantly lower treatment costs by 50–75%.

India has a strong pharma network, with more than 10,000 manufacturing facilities, over 3,000 pharma companies.

"This important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...